US FDA gave a complete response letter to Genzyme over Lemtrada, which means their application for its multiple scleroisis drug is been rejected. According to FDA, Genzyme was not able to provide sufficent advantage of the drug over its side effects!

Lemtrada is approved in the European Union, Canada, and Australia, and additional marketing applications for Lemtrada are under review by regulatory agencies around the world.